FRACTION-RCC: innovative, high-throughput assessment of nivolumab plus ipilimumab (N+I) for treatment-refractory advanced renal cell carcinoma (aRCC)

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

10-2020

Volume

43

Issue

1

Published In/Presented At

https://doi.org/10.1159/000510995

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article